Precision Gene Guided Nutrition
SNP Therapeutics is a research based genomics company with a focus on issues in metabolism that contribute to diseases and other health related issues. SNP Therapeutics evaluates each patients' genome and translates it into meaningful, actionable information by utilizing the companies proprietary custom genetic test and algorithms.
SNP Therapeutics identifies variants (i.e. genetic misspellings or mutations called "SNPs" - pronounced snips) that contribute to diseases. These SNP patterns the company is identifying are responsible for causing metabolic and nutrient inefficiencies which contribute to many of the health problems people face today. The company develops propitiatory genetic test and algorithms to identify various metabolic gene variants (SNPs) based on clinical research and trials.
Once SNP Therapeutics has evaluated a patients' genome data, the company can provide information to patients and physicians so treatment options can be explored. Physicians can prescribe a scientifically based medical food solutions for many of these medical conditions. SNP Therapeutics develops medical nutrition that is based on validated, clinical studies and provides highly curative results for patients.
Mr. Kleu has devoted his entire career to building commercial teams and developing strategies for various companies within the pharmaceutical industry. Prior to SNP Therapeutics, Mr. Kleu began his career with the Upjohn Company (Pfizer) where he worked in various commercial leadership roles before joining Daiichi Sankyo as an inaugural member of the management team charged with building its’ first U.S. commercial presence. Mr. Kleu served as Vice President of Sales for Daiichi Sankyo, (a global pharmaceutical company; top 20 worldwide). Mr. Kleu was a member of the executive management team that built the US Commercial division to over 3,000 employees and $3B in annual US revenue through the launch of 6 successful brands in 15 years. Over the past 5 years Mr. Kleu has worked as a Vice President for the commercial division of Syneos Health (Nasdaq:SYNH), a fully integrated biopharmaceutical solutions provider, specializing in Contract Research and Contract Commercial solutions for the pharma sector). He has partnered with a number of major companies to build and execute commercial strategies for many successful brands (i.e., J&J, Pfizer, Eli Lilly, and Forest Labs). While at Syneos Health Mr. Kleu has also been successful in building commercial strategies for new start-up companies by providing a variety of services from his teams to clients, (i.e., consulting, marketing, operations, compliance, legal, compensation, medical, payer reimbursement, recruiting, and training). Mr. Kleu is a graduate of The University of North Carolina at Greensboro with a major in Business Administration and a concentration in Marketing. Jon and his family reside in the Raleigh, North Carolina area.
Steven Zeisel, MD, PhD is the Director of the University of North Carolina's Nutrition Research Institute, a world-renowned scientist and a Kenan Distinguished University Professor in Nutrition and Pediatrics. Dr. Zeisel is internationally recognized for his research in nutrigenetics and nutrient requirements. Dr. Zeisel is the Kenan Distinguished University Professor in the Department of Nutrition in the Gillings School of Global Public Health and School of Medicine at the University of North Carolina at Chapel Hill. Dr. Zeisel earned his MD from Harvard Medical School in 1975, was a resident in pediatrics at Yale University from 1975–1977, and earned his PhD in nutrition at the Massachusetts Institute of Technology in 1980. He served as chair of the Department of Nutrition at UNC from 1990-2005. Dr. Zeisel is the Director of the UNC Nutrition Research Institute and Director of the UNC Nutrition and Obesity Research Center (one of 12 centers of excellence funded by the US National Institutes of Health). Dr. Zeisel serves on the Federation of American Societies for Experimental Biology (FASEB) Journal editorial board. His research team focuses on the essential nutrient choline and why there are individual differences in nutrient metabolism, using new approaches in nutrigenetics and metabolomics. Dr. Zeisel has proven that humans require choline and that this nutrient is critical for normal brain development, and for liver and muscle function. Based on his research, the US Institute of Medicine set a dietary requirement for choline in 1998. Currently, Zeisel’s team is investigating how gene misspellings alter dietary requirements, how diet can add marks to genes which turn them on an off (epigenetics), and how choline is needed for normal liver, muscle and sperm function. All of these studies have been supported by grants from the US National Institutes of Health. Dr. Zeisel has authored more than 350 scientific publications and has won numerous awards including the prestigious National Institute of Environmental Health Sciences’ Falk Award, the American Society for Nutrition’s Osborne and Mendel Award, the American College of Nutrition’s Award
Copyright © 2020 SNP Therapeutics, LLC - All Rights Reserved.